Drugs / AMILOMOTIDE
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00411580 | Jun 2005 → Dec 2008 | Alzheimer disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01023685 | Dec 2009 → Feb 2012 | Alzheimer disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00956410 | Sep 2009 → Jun 2011 | Alzheimer disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00795418 | Oct 2008 → Nov 2010 | Alzheimer disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00733863 | Jul 2008 → Feb 2010 | Alzheimer disease | Novartis | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02565511 | Nov 2015 → Apr 2020 | Alzheimer disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01097096 Comparator | Mar 2010 → Dec 2012 | Alzheimer disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMILOMOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108328 ↗ |
| Known as | Amilomotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108328 ↗ |
| Known as | CAD106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01097096 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108328 ↗ |
| Route | Subcutaneous | “Each patient received three subcutaneous injections.” PMID 22677258 ↗ Jun 2012 |
| Target | APP | “Amyloid-beta A4 protein vaccine antigen” CHEMBL2108328 ↗ |